Zoll signs supply deal with Novation:
This article was originally published in Clinica
Executive Summary
Zoll Medical has made a three-year agreement with Novation, the supply company for US US health alliances VHA and the University HealthSystem Consortium. Under the agreement, which includes two one-year renewal options, Burlington, Massachusetts-based Zoll will be the dual-source provider of cardiac resuscitation products - including external defibrillators/pacemakers, automated external defibrillators and automated advisory defibrillators - for Novation customers. Novation, which is based in Irving, Texas, represents more than 6,000 healthcare organisations in the US. It manages over $12 billion in annual supply purchases.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.